Investors & News / Media Coverage / Media Coverage Year None202420222020201920172016 Oct 31, 2024 Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis Aug 23, 2024 Podcast: Improving Targeting and Penetration of Cancer Therapies for Solid Tumors by Modifying Tumor Microenvironment with David Mazzo Lisata Therapeutics Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research Jul 17, 2024 BioHub Podcast with Dr. David Mazzo, CEO of Lisata Therapeutics Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI Jul 11, 2024 Lisata’s Certepetide: promising preclinical results in cholangiocarcinoma Jul 08, 2024 Lisata Therapeutics embarks on cancer-fighting campaign Jun 07, 2024 Pharma’s R&D gamble: picking pipeline winners in a risky field May 29, 2024 How does Lisata Therapeutics have a negative enterprise value? Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Print Page RSS Feeds Email Alerts
Year None202420222020201920172016 Oct 31, 2024 Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis Aug 23, 2024 Podcast: Improving Targeting and Penetration of Cancer Therapies for Solid Tumors by Modifying Tumor Microenvironment with David Mazzo Lisata Therapeutics Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research Jul 17, 2024 BioHub Podcast with Dr. David Mazzo, CEO of Lisata Therapeutics Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI Jul 11, 2024 Lisata’s Certepetide: promising preclinical results in cholangiocarcinoma Jul 08, 2024 Lisata Therapeutics embarks on cancer-fighting campaign Jun 07, 2024 Pharma’s R&D gamble: picking pipeline winners in a risky field May 29, 2024 How does Lisata Therapeutics have a negative enterprise value? Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
Oct 31, 2024 Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis
Aug 23, 2024 Podcast: Improving Targeting and Penetration of Cancer Therapies for Solid Tumors by Modifying Tumor Microenvironment with David Mazzo Lisata Therapeutics
Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research
Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer
Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI
